A recent study published in the New England Journal of Medicine highlights the role of inflammatory markers in predicting cardiovascular risk and monitoring coronary artery disease (CAD).

The research involved nearly 30,000 women from the Women's Health Study, who were followed for 30 years after starting the study between 1992 and 1995.

Findings revealed that women with the highest levels of inflammation had a 70% increased risk of significant heart events compared to those with the lowest levels.

The study specifically identified three crucial biomarkers: low-density lipoprotein (LDL) cholesterol, lipoprotein(a) [Lp(a)], and C-reactive protein (CRP).

Dr. Paul Ridker, the study's lead author, advocates for routine testing of Lp(a), LDL, and CRP in patients in their 30s or 40s to facilitate early intervention.

Coronary artery disease is increasingly recognized as an inflammatory process rather than solely a result of cholesterol accumulation.

While lifestyle changes are beneficial, the study suggests that medication may be necessary for individuals with elevated levels of these inflammatory markers.

Although the study focused on women, researchers believe that similar results would likely apply to men.

The methodology included collecting blood samples and analyzing various biomarkers using ELISA kits to assess CAD severity.

The research combined results from three specific tests to evaluate the likelihood of major cardiovascular events in healthy women.

Dr. Ridker emphasizes the importance of including Lp(a) and CRP levels in cardiovascular risk assessments to enhance early detection and prevention efforts.

The study's findings contribute to advancing the identification and prevention of heart disease, as discussed at the recent European Society of Cardiology Congress.